2022
Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma
Cheraghlou S, Ugwu N, Girardi M. Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma. JAMA Dermatology 2022, 158: 51-58. PMID: 34878492, PMCID: PMC8655663, DOI: 10.1001/jamadermatol.2021.4812.Peer-Reviewed Original ResearchConceptsAcral lentiginous melanomaNational Cancer DatabaseClinical stage IBSLN positivityStage IBSentinel lymphCutaneous melanomaPositivity rateMalignant melanomaHigh riskSentinel lymph node statusAJCC Cancer Staging ManualClinical stage IRetrospective cohort studySignificant prognostic factorsLymph node statusCancer Staging ManualMultivariable logistic regressionHigher positivity rateAJCC clinical stageCohort studySLN statusPrognostic factorsSuch patientsStaging Manual
2010
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 2010, 63: 975-983. PMID: 20888065, DOI: 10.1016/j.jaad.2009.12.052.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaToll-like receptor 9 agonistPF-3512676Receptor 9 agonistT-cell lymphomaSézary syndromeMycosis fungoidesIVa cutaneous T cell lymphomaRefractory cutaneous T-cell lymphomaPhase I dose-escalation studyI dose-escalation studyClass of lymphomasIndex Lesion SeverityClinical response rateCommon adverse eventsPhysician global assessmentPrimary end pointDose-escalation studyPhase I trialWeekly subcutaneous injectionsLimited therapeutic optionsTreatment of patientsEnd of studyStage IBAdverse events